Yield10 Bioscience Dirección

Dirección controles de criterios 3/4

El CEO de Yield10 Bioscience's es Olly Peoples , nombrado en Oct 2016, tiene una permanencia de 7.5 años. compensación anual total es $527.47K, compuesta por 62.7% salario y 37.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.48% de las acciones de la empresa, por valor de $19.06K. La antigüedad media del equipo directivo y de la junta directiva es de 7.5 años y 7.6 años, respectivamente.

Información clave

Olly Peoples

Chief Executive Officer (CEO)

US$598.6k

Compensación total

Porcentaje del salario del CEO	57.5%
Permanencia del CEO	7.6yrs
Participación del CEO	0.5%
Permanencia media de la dirección	7.6yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Olly Peoples en comparación con los beneficios de Yield10 Bioscience?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$599k	US$344k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$527k	US$331k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$315k	-US$11m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$1m	US$289k	-US$10m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$600k	US$275k	-US$13m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$738k	US$275k	-US$9m
Sep 30 2018	n/a	n/a	-US$11m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$382k	US$225k	-US$11m

Compensación vs. Mercado: La compensación total ($USD527.47K) de Olly está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Olly ha aumentado mientras la empresa no es rentable.

CEO

Olly Peoples (65 yo)

7.6yrs

Permanencia

US$598,554

Compensación

Dr. Oliver P. Peoples, also known as Olly, Ph D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Oliver Peoples	Co-Founder	7.6yrs	US$598.55k	0.48% $ 6.6k
Kristi Snell	VP of Research & Chief Science Officer	7.6yrs	US$406.26k	0.27% $ 3.6k
Lynne Brum	VP of Planning & Corporate Communications and Secretary	7.6yrs	US$366.98k	0.26% $ 3.5k
Charles Haaser	VP of Finance	9.5yrs	US$251.94k	0.27% $ 3.6k

7.6yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de YTEN es experimentado (7.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Oliver Peoples	Co-Founder	31.9yrs	US$598.55k	0.48% $ 6.6k
Richard Hamilton	Independent Director	7.2yrs	US$74.84k	0.47% $ 6.4k
Robert Van Nostrand	Independent Chairman of the Board	17.6yrs	US$84.84k	0.32% $ 4.3k
Anthony Sinskey	Independent Director	31.9yrs	US$74.84k	0.42% $ 5.7k
Heike Sederoff	Member of Scientific Advisory Board	7.7yrs	sin datos	sin datos
Danny Schnell	Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Jay Thelen	Member of Scientific Advisory Board	5.8yrs	sin datos	sin datos
Sherri Brown	Independent Director	4.3yrs	US$57.34k	0% $ 0
Willie Loh	Independent Director	1.6yrs	US$57.34k	0% $ 0

7.7yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de YTEN se considera experimentada (7.6 años de antigüedad promedio).

Yield10 Bioscience Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Recent updates

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

Consensus revenue estimates fall to US$1.08m

First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Consensus forecasts updated

Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)

Yield10 Bioscience, Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day high: US$18.86

Yield10 Bio secures $12.7M capital raise

Yield10 Bioscience under pressure on launching stock offering

When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?